Impact of Golimumab, An Anti-Tnfα Monoclonal Antibody, On Health Related Quality of Life (Hrqol) And Work Productivity In Patients With Active Psoriatic Arthritis- 24-Week Results of The Phase Iii Go Vibrant Trial

Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.788
https://www.valueinhealthjournal.com/article/S1098-3015(17)31122-1/fulltext
Section Title : Disease-Specific Studies
Section Order : 755
First Page : A538
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31122-1&doi=10.1016/j.jval.2017.08.788
HEOR Topics :
Tags :
Regions :